Ohio State Hosts National Roundtable on
OSUCCC - James Roundtable #1
OSUCCC - James Roundtable #2
OSUCCC - James Roundtable #3
OSUCCC - James Roundtable #4
OSUCCC - James Roundtable #5
OSUCCC - James Roundtable #6
Drug Development Institute will Expedite Clinical Research
An effort to create the Ohio State Drug Development Institute got under way in 2011, launched by the OSUCCC – James in collaboration with leaders in the colleges of Medicine, Pharmacy and Business. The institute will create a cancer drug development pipeline for taking new compounds through phase II clinical trials. Timothy Wright, a former executive of several pharmaceutical companies, was recruited to direct this effort in conjunction with Brian Cummings, the University’s lead for technology commercialization.
Ohio State Selected for Cancer Immunotherapy Trials Network
The Ohio State University is one of 27 research institutions in North America selected to join the Cancer Immunotherapy Trials Network (CITN) funded by the National Cancer Institute (NCI). William Carson III, MD, associate director for clinical research at the OSUCCC – James, is principal investigator for the project at Ohio State. As a new initiative in immunotherapy, the CITN will establish a group of top academic immunologists to conduct multicenter research on agents that boost patients’ immune systems to fight their cancer. The NCI held an open competition for institutions to apply for member-site status in the CITN.
© The Ohio State University